Akynzeo was launched in the United States in December 2014 [1]. The oral fixed-dose combination of netupitant and palonosetron, marketed as Akynzeo, received FDA approval for the prevention of chemotherapy-induced nausea and vomiting (CINV) [2].
When did Akynzeo become available in other countries?
Akynzeo's availability has expanded globally since its U.S. launch. In Europe, it received marketing authorization from the European Medicines Agency (EMA) in October 2015 [3]. The drug has also been approved and launched in other markets, including Japan and Canada [4][5].
What is Akynzeo used for?
Akynzeo is prescribed to prevent acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy [2]. It is also indicated for patients receiving moderately emetogenic cancer chemotherapy [2]. The medication works by blocking the action of substance P and neurokinin 1 (NK1) receptors, as well as serotonin receptors, to reduce nausea and vomiting [2].
What are the key components of Akynzeo?
Akynzeo is a fixed-dose combination therapy containing two active ingredients: netupitant and palonosetron [2]. Netupitant is a selective NK1 receptor antagonist, and palonosetron is a selective 5-HT3 receptor antagonist [2].
Who manufactures Akynzeo?
Akynzeo was developed by Helsinn Healthcare SA [3]. The drug is marketed in the United States by U.S. Pharmaceutical, a subsidiary of AmerisourceBergen [1]. In other regions, it is marketed by various partners [3].
What is the patent status for Akynzeo?
Information regarding Akynzeo's patent status can be found on DrugPatentWatch.com [6]. Patent expiration dates are crucial for determining when generic versions of a drug may become available.
---
Sources
[1] https://www.drugpatentwatch.com/drugs/akynzeo
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/akynzeo-package-insert
[3] https://www.helsinn.com/en/news/akynzeo-receives-positive-opinion-chmp-eu
[4] https://www.helsinn.com/en/news/helsinn-announces-regulatory-submission-akynzeo-japan
[5] https://www.helsinn.com/en/news/akynzeo-approved-canada
[6] https://www.drugpatentwatch.com/